



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>7</sup> :</b><br><b>A61K 9/00, 47/00, 31/66</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 00/61111</b><br><b>(43) International Publication Date:</b> 19 October 2000 (19.10.00)   |
| <b>(21) International Application Number:</b> PCT/SE00/00664<br><b>(22) International Filing Date:</b> 6 April 2000 (06.04.00)<br><b>(30) Priority Data:</b><br>9901272-6                      9 April 1999 (09.04.99)                      SE<br><b>(71) Applicant (for all designated States except US):</b> AS-<br>TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> LINDFORS, Lennart<br>[SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal<br>(SE). LÖFROTH, Jan-Erik [SE/SE]; AstraZeneca R &<br>D Mölndal, S-431 83 Mölndal (SE). SJÖGREN, Sven<br>[SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal<br>(SE). UNGELL, Anna-Lena [SE/SE]; AstraZeneca R & D<br>Mölndal, S-431 83 Mölndal (SE).<br><b>(74) Agent:</b> ASTRAZENECA AB; Global Intellectual Property,<br>Patents, S-151 85 Södertälje (SE). |           | <b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB,<br>BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM,<br>DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,<br>IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,<br>LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,<br>RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,<br>UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH,<br>GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian<br>patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European<br>patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,<br>IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,<br>CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> <u>A PHARMACEUTICAL FORMULATION COMPRISING AN BISPHOSPHONATE AND AN ADDITIVE AGENT PROVIDING AN ENHANCED ABSORPTION OF THE BISPHOSPHONATE</u>   |           |  |
| <b>(57) Abstract</b><br><br>The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.   |           |  |

## ABSTRACT

The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.